ERLOTINIB TABLET 100MG & 150 MG

Get Latest Price

Packaging TypePlastic Bottle
UsageClinical, hospital etc.
FormTablets / Liquid / Capsules / Powder
StorageCool and Dry Place
Supply TypeManufacturer, Exporter, Supplier, Retailer
Preferred Buyer Location All over the world

View More Details

Send Enquiry

Company Information

3S Corporation

Kandivali East, Mumbai, Maharashtra

View Number

Member Since 14 Years
Nature of Business Retailer
GST No. 27AAHPM3187H1ZG

Ask for more detail from the seller

Contact Supplier

Report incorrect details

View Company Details

Product Details
Company Details

Packaging TypePlastic Bottle
UsageClinical, hospital etc.
StorageCool and Dry Place
Dosage5mg
FormTablets / Liquid / Capsules / Powder
Grade StandardMedicine Grade
CATEGORYAnti Cancer Tablets
StorageCool and Dry Place

Erlotinib Tablet is indicated for:

The first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor(EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
The maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer, whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
The treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of at least one prior chemotherapy regimen.

3s corporation is Supplier,Exporter ,Wholesaler for Erlotinib Tablet 100mg & 150 mg in India.

We even offer contract manufacturing services from WHO GMP approved factories.

ADDITIONAL INFORMATION

Single oral doses of Erlotinib up to 1,000 mg in healthy subjects and weekly doses up to 1,600 mg in cancer patients have been tolerated. Repeated twice-daily doses of 200 mg single-agent Erlotinib in healthy subjects were poorly tolerated after only a few days of dosing. Based on the data from these studies, an unacceptable incidence of severe adverse reactions, such as diarrhea, rash, and liver transaminase elevation, may occur above the recommended dose.

SIDE EFFECTS-

MOST COMMON SIDE EFFECTS

Metastatic NSCLC – First-Line Treatment of Patients With EGFR Mutations:
- Most frequent (≥30%) adverse reactions were diarrhea, asthenia, rash, cough, dyspnea, and decreased appetite.
Advanced NSCLC – Maintenance Treatment:
- Rash and diarrhea.
- Rash (9%) and diarrhea (2%). Rash and diarrhea resulted in dose reductions or interruption (5% and 3%, respectively) and discontinuation (1% and 0.5%, respectively) of Erlotinib-treated patients.
Advanced NSCLC – Second/Third-Line Treatment:
- Rash and diarrhea.
- Rash (9%) and diarrhea (6%). Rash and diarrhea each resulted in dose reductions (6% and 1%, respectively) and discontinuation in 1% of Erlotinib-treated patients.
Advanced Pancreatic Cancer –Erlotinib Administered Concurrently with Gemcitabine:
- Fatigue, rash, nausea, anorexia, and diarrhea.
- Grade 3/4 (NCI-CTC Version 2.0) adverse reactions were rash (5%) and diarrhea (5%). Rash and diarrhea each resulted in dose reductions in 2% of patients and discontinuation in up to 1% of patients receiving Erlotinib plus gemcitabine.